€30m raised for first-in-class in vivo cell reprogramming platform
Drug Discovery World
MARCH 19, 2024
Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprogrammes tumour cells into antigen-presenting dendritic cells, ultimately leading to a personalised anti-tumour immune response.
Let's personalize your content